今日要闻！《声生不息·宝岛季》唱响时代新篇章，两岸同胞共谱华流金曲新篇章

《声生不息·宝岛季》唱响时代新篇章，两岸同胞共谱华流金曲新篇章

长沙/台北讯 由芒果TV、湖南卫视、TVBS三家联合制作的音乐文化交流节目《声生不息·宝岛季》，自3月16日起每周四晚20:10在芒果TV、湖南卫视播出，并在TVBS欢乐台、TVBS新闻台同步播出，节目以年代为线索，邀请两岸12位歌手隔空献唱华语金曲，共谱两岸音乐新篇章。

节目开播以来，收视率一路飙升，引发了全社会对华语音乐的广泛关注和热烈讨论。截止目前，节目微博话题阅读量已超过30亿，相关短视频播放量超过100亿，节目可谓是收视口碑双丰收。

以乐会友，唱响时代新篇章

《声生不息·宝岛季》延续了第一季“以歌会友”的理念，邀请了两岸12位实力唱将同台献唱。来自中国大陆的张信哲、那英、杨宗纬、张韶涵、魏如萱、张杰、华晨宇、时代少年团马嘉祺，以及来自台湾的林宥嘉、萧敬腾、李玟、艾怡良，共同演绎了近40首华语金曲。

节目中，歌手们跨越时代、隔空对话，用歌声传递着两岸同胞的血脉亲情和文化认同。张信哲深情演唱的《爱如潮水》，那英霸气十足的《征服》，杨宗纬感人肺腑的《一次就好》，张韶涵甜美灵动的《欧若拉》，魏如萱率性洒脱的《末路狂花》，张杰震撼人心的《明天会更好》，华晨宇充满力量的《寒武纪》，时代少年团马嘉祺青春洋溢的《少年时代》，林宥嘉温柔细腻的《眼眶》，萧敬腾充满爆发的《王妃》，李玟性感火辣的《刀马旦》，艾怡良细腻动人的《爱情故事》，都给观众留下了深刻的印象。

节目创新，打造多重看点

除了精彩的歌声之外，《声生不息·宝岛季》在节目形式和舞美设计上也进行了大胆创新，打造了多重看点。

节目以“年代秀”的形式呈现，每个节目围绕一个年代展开，通过歌手们的演唱和讲述，带领观众重温那个年代的华语音乐风华。

节目的舞美设计也十分巧妙，将两岸的经典元素融合在一起，营造出浓浓的怀旧氛围。在长沙主会场，舞台中央的“日月潭”造型十分吸睛，而台北分会场的“台北101”造型也展现了台湾的独特风情。

全民共唱，华流金曲再创辉煌

《声生不息·宝岛季》的播出，不仅引发了全社会对华语音乐的关注和讨论，也让更多人了解了两岸音乐的渊源和发展。节目中，许多经典金曲被重新演绎，焕发了新的生命力，也吸引了更多年轻观众关注华语音乐。

在节目播出期间，许多观众自发组织“K歌会”，一起唱响华语金曲。在社交平台上，也涌现出了大量网友翻唱节目的视频。

《声生不息·宝岛季》的成功，不仅是两岸音乐文化交流的一次成功实践，也是华语音乐发展的一次重要契机。相信在未来，华语音乐将继续发扬光大，唱响更动人的旋律，传递更真挚的情感。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.